Concepedia

Taro Okamoto

TO

Statistics

Publications

13

Citations

463

H-Index

13

Active since

1992

Affiliations

Hiroshima University(Current)

Merck & Co., Inc., Rahway, NJ, USA (United States)

MSD K.K. (Japan)

The University of Tokyo

Ono Pharmaceutical (Japan)

Taro Okamoto is an author at Hiroshima University specializing in medicine, diabetes mellitus, and pharmacology.

ORCID

Publications per year

1992–2017

13

Publications

13

Dose-ranging efficacy of sitagliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus

Yasuhiko Iwamoto, Tadaaki Taniguchi, Kenji Nonaka et al. · Endocrine Journal · 2010 · 100 citations · Full text

, , +17

Day-of-Surgery Mobilization Reduces the Length of Stay After Elective Hip Arthroplasty

Taro Okamoto, Ryan J. Ridley, Stephen J. Edmondston et al. · The Journal of Arthroplasty · 2016 · 77 citations

, , +10

Valproic acid induces apoptosis dependent of Yca1p at concentrations that mildly affect the proliferation of yeast

Kazuhiro Mitsui, Daichi Nakagawa, Masahiro Nakamura et al. · FEBS Letters · 2005 · 55 citations

, , +16

Serum levels of glucose-derived advanced glycation end products are associated with the severity of diabetic retinopathy in type 2 diabetic patients without renal dysfunction.

Kiyoshi Koga, Sho‐ichi Yamagishi, Taro Okamoto et al. · PubMed · 2002 · 40 citations

, , +12

A randomized, placebo‐ and sitagliptin‐controlled trial of the safety and efficacy of omarigliptin, a once‐weekly dipeptidyl peptidase‐4 inhibitor, in <scp>J</scp> apanese patients with type 2 diabetes

Ira Gantz, Taro Okamoto, Yuka Ito et al. · Diabetes Obesity and Metabolism · 2017 · 34 citations · Full text

, , +14

1–5 of 13